Clonidine reduces hyperpolarization-activated inward current (Ih) in rat hypoglossal motoneurons.
We used intracellular recording techniques to investigate the actions of clonidine on hypoglossal motoneurons (HMs) in rat brainstem slices. Clonidine (10-100 microM) produced a small (2-6 mV), dose-dependent hyperpolarization in HMs, accompanied by an increase in peak input resistance (RN). It also slowed the time course of the depolarizing 'sag' of the voltage response to constant hyperpolarizing current steps. These effects were mimicked by the alpha2-adrenoceptor (alpha2-AR) agonist guanabenz, but not by the Ih-imidazoline receptor agonists moxonidine or rilmenidine. Recorded in single-electrode voltage clamp mode, clonidine decreased input conductance of HMs and reduced the amplitude of a hyperpolarization-activated inward current (Ih). Clonidine's effect on Ih was three-fold: it shifted the half-activation voltage (V1/2) in the hyperpolarizing direction (by 4.4 +/- 0.7 mV at a dose of 10 microM), decreased the maximal current (by approximately 20%), and slowed the time course of Ih activation at all voltage steps. At the most hyperpolarized potential steps, clonidine slowed activation of Ih dramatically, yielding a striking increase in the activation time constant. The alpha2-AR antagonists yohimbine and idazoxan reduced clonidine's effect on V1/2 and on the Ih activation time course, but neither blocked clonidine's reduction of the maximal current, nor its strong slowing of Ih activation at the most hyperpolarized steps. We were unable to mimic or occlude clonidine's actions with the adenylate cyclase inhibitor SQ 22536 nor with the non-specific protein kinase inhibitor H-7. We conclude that clonidine hyperpolarizes HMs via a reduction of the amount of Ih that is active at rest, and that the response is mediated in part by alpha2-ARs. Some effects of clonidine on these neurons do not appear to be receptor-mediated, and may be due to physical block by clonidine of Ih channels.
Parkis
M A
MA
Department of Physiology and Biophysics, School of Medicine, University of Washington, Seattle 98195-7290, USA.
Berger
A J
AJ
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000494:pharmacology; D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology; D000067956:Adenylyl Cyclase Inhibitors; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D003000:Clonidine / Q000494:pharmacology*; D004594:Electrophysiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D007002:Hypoglossal Nerve / Q000166:cytology / Q000187:drug effects* / Q000502:physiology*; D008297:Male; D009046:Motor Neurons / Q000187:drug effects* / Q000502:physiology*; D018408:Patch-Clamp Techniques; D047428:Protein Kinase Inhibitors; D051381:Rats; D017207:Rats, Sprague-Dawley
D000067956:Adenylyl Cyclase Inhibitors; D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D047428:Protein Kinase Inhibitors; C017759:9-(tetrahydro-2-furyl)-adenine; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D000225:Adenine; D003000:Clonidine